Navigation Links
BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
Date:8/22/2007

ther this important work."

"We are pleased to add this program to our growing product development pipeline. The cystic fibrosis indication aligns well with our existing product portfolio and core competencies as it is a well-defined and relatively large orphan disease," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin. "It has a clear clinical and regulatory path and will allow us to leverage our commercial infrastructure targeting specialists."

Cystic fibrosis is an autosomal recessive disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. With an incidence of approximately 1/3,500 births, cystic fibrosis is the most common, lethal genetic disease in the U.S. CF affects an estimated 30,000 patients in the U.S. and approximately 40,000 patients outside the U.S. CFTR is a transmembrane protein that functions primarily as a chloride channel in the plasma membrane of epithelial cells. The most common mutation in cystic fibrosis, the deltaF508 mutation, causes the protein to be misfolded and through a cascade of events, leads to mucus buildup and ultimately, organ dysfunction and severe infections in the lungs. The median age of survival of a CF patient is 36.5 years.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio is comprised of two approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation. Investigational product candidates include Kuvan(TM) (sapropterin dihydrochloride), a Phase 3 product candidate for the treatment of phenylketonuria (PKU), and 6R-BH4 fo
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GenTel licenses next generation cancer research
2. Third Wave licenses Innogenetics tech to settle lawsuit
3. WARF licenses patents for new glaucoma drug treatment
4. PKWARE Licenses Technology to Expand SecureZIP Standard
5. Mentor Licenses Botulinum From WARF and Plans Wisconsin Manufacturing Facility
6. Innovative Tissue Array Technology for High-Throughput Screening of Gene Expression
7. HotMasterAn innovative Hot Start/Cold Stop technology for better PCR* results
8. Enhancing Ruggedness and Full-Scan MS Sensitivity Using Ion Sweep Technology
9. Novel MicroRNA Array Technology for Sensitive miRNA Profiling
10. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
11. Use of FlashPlate Technology for In Vitro Measurement of [35S]-GTPγS Binding in CHO Cells Expressing the Human 5-HT1B Receptor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Biofertilizers stimulate microbial activities in soil. These microorganisms ... the activities in the soil or in the rhizosphere. ... stress on reducing environmental pollution and on reducing the ... segments the bio fertilizers market with analysis and forecasting ...
(Date:1/22/2015)... today announces the firm brokered a long-term lease totaling 202,492 ... company, at Two Ledgemont Center in Lexington, Massachusetts ... and Brian Cohen , senior vice president, represented Shire ... Hayden Ave. Photo - http://photos.prnewswire.com/prnh/20150122/170765 ...
(Date:1/22/2015)... Protocol Networks brings independent technology consulting to ... independent consultants, Protocol Networks has recently announced its expansion ... years, his company has attracted several clients in The ... well as others. With the success of these engagements, ...
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a project managed ... legal requirements around using controlled substances in pharmaceutical research, ... their international operations expand and become increasingly complex, large ... a result of the first phase of the CSCS ...
Breaking Biology Technology:Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 2Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 3Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 4Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Global Compliance Service for Controlled Substances to Expand to China 2
... Dec. 7 CVF Technologies,Corporation,s (OTC Bulletin Board: CNVT) ... a customer in Beijing, China for a,Biofiltair odor control ... China to approximately $500,000 (Cdn) and is the third ... "We are pleased that our technology was accepted on ...
... 7 Tutogen Medical, Inc.,(Amex: TTG ), a ... (allograft) and animal (xenograft) tissue, will report,financial results for ... on Monday, December 10, 2007 at 4:30 p.m. ET., ... (888) 408-9532 or,(706) 679-5064 or by accessing the web ...
... Products for the Long-Term Care Channel, ... Inc., wholly owned subsidiary of Millennium Biotechnologies,Group, ... that the initial,$200,000.00 monthly shipment from Millennium ... under the previously announced $20,000,000,Five- year exclusive ...
Cached Biology Technology:CVF Technologies Corporation's Holding - BIOREM Announces 3rd Order from China 2Tutogen Medical, Inc. to Report Fourth Quarter and Fiscal Year 2007 Financial Results 2Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order 2Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order 3
(Date:12/19/2014)... Calif. , Dec. 18, 2014  23andMe, Inc., the leading ... that pinpoints fine-scale differences in genetic ancestry of individuals from ... Since immigrants first arrived more than four hundred years ago, ... a meeting place for peoples from different continents. This study ...
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM announced ... audit to confirm its adherence to current U.S. Food ... to conduct regulated smart device and smart phone application ... research quality. "HITLAB is determined to improve ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a technology ... measures the overall facial feature of a person such ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... Institute for Biological Studies discovered that cells co-opted the ... protect the integrity of chromosomes. This finding solves for ... puzzled scientists. , The natural ends of chromosomes look ... repair machinery is designed to fix. But mending chromosome ...
... very earliest genetic changes involved in the development of lung ... mouse that develops the disease in much the same way ... 1 issue of Cancer Research, open the door to the ... the very first signs of lung cancer, when the possibility ...
... pathogenic fungi as model systems for understanding fungal diseases, ... offers insight into how carbon dioxide (CO2) governs the ... different environments and invade the human body, and they ... utilize evolutionarily conserved enzymes to control the growth and ...
Cached Biology News:Normal chromosome ends elicit a limited DNA damage response 2Building a better mouse model of lung cancer: FHIT counts 2Building a better mouse model of lung cancer: FHIT counts 3CO2 sensing proves critical for fungal pathogens to adapt to life in air and human hosts 2CO2 sensing proves critical for fungal pathogens to adapt to life in air and human hosts 3
Anti-Mouse Macrophages (Metallophillic), Purified (Clone MOMA-1) (rat IgG2a)...
Request Info...
Human Osteocalcin (1-22) mature form. Also reacts with Osteocalcin (1-44) and Osteocalcin (1-49). No reactivity with Bone sialoprotein....
TGF-beta 1,-2,-3 MAb (Clone 1D11)...
Biology Products: